ArticleInternational ophthalmology2025
Investigating clues of cystoid macular edema from a vascular perspective under long-term latanoprost usage.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the macular vascular effects of prolonged use of latanoprost compared to the dorzolamide-timolol fixed combination in patients with very early-stage glaucoma, where glaucoma-specific damage has been minimized.
methodsThe retinal vascular effects of latanoprost versus the dorzolamide-timolol fixed combination were evaluated using Optical Coherence Tomography Angiography (OCT-A) in a case-control study design. A total of 71 eyes from 71 individuals were included in the study: 28 eyes receiving latanoprost (Group 1), 20 eyes receiving the dorzolamide-timolol combination (Group 2), and 23 eyes from healthy individuals (Group 3). Superficial, deep, and radial peripapillary capillary plexus vascular density (SCP-vd, DCP-vd, RPCP-vd) and foveal avascular zone (FAZ) measurements were taken with OCT-A. The comparative analysis between groups was performed with SPSS V.26.
resultsAcross the groups (from 1 to 3), whole image vascular density (vd) measurements were as follows: SCP-vd: 45.86 ± 3.99, 44.58 ± 4.58, 48.35 ± 4.04; DCP-vd: 44.86 ± 5.75, 44.02 ± 6.87, 49.74 ± 4.84; and RPCP-vd: 46.97 ± 3.81, 47.07 ± 5.49, 49.90 ± 2.43. All these measurements were significantly decreased in both glaucoma groups (groups 1 and 2) compared to healthy subjects (group 3). In subgroup analyses of the macular region, including the fovea, parafovea, and perifovea, vd measurements were decreased in all areas except the fovea in glaucoma patients. However, no statistically significant differences were found between the latanoprost and dorzolamide-timolol groups regarding retinal vascular structure. In FAZ measurements, no significant differences were found in any anatomical location among the three groups.
conclusionThis study demonstrates that latanoprost, the first prostaglandin analog known for its edema-inducing effect on the macula, does not have a long-term impact on macular vascularity. However, this result should be supported with longer and larger studies.
Indexed as
Identifiers
40347381What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.